Inoculum Effect with Cefazolin among Clinical Isolates of Methicillin-Susceptible Staphylococcus aureus : Frequency and Possible Cause of Cefazolin Treatment Failure

Antimicrobial Agents and Chemotherapy
2009.0

Abstract

Methicillin (meticillin)-susceptible Staphylococcus aureus (MSSA) strains producing large amounts of type A beta-lactamase (Bla) have been associated with cefazolin failures, but the frequency and impact of these strains have not been well studied. Here we examined 98 MSSA clinical isolates and found that 26% produced type A Bla, 15% type B, 46% type C, and none type D and that 13% lacked blaZ. The cefazolin MIC(90) was 2 microg/ml for a standard inoculum and 32 microg/ml for a high inoculum, with 19% of isolates displaying a pronounced inoculum effect (MICs of >or=16 microg/ml with 10(7) CFU/ml) (9 type A and 10 type C Bla producers). At the high inoculum, type A producers displayed higher cefazolin MICs than type B or C producers, while type B and C producers displayed higher cefamandole MICs. Among isolates from hemodialysis patients with MSSA bacteremia, three from the six patients who experienced cefazolin failure showed a cefazolin inoculum effect, while none from the six patients successfully treated with cefazolin showed an inoculum effect, suggesting an association between these strains and cefazolin failure (P = 0.09 by Fisher's exact test). In summary, 19% of MSSA clinical isolates showed a pronounced inoculum effect with cefazolin, a phenomenon that could explain the cases of cefazolin failure previously reported for hemodialysis patients with MSSA bacteremia. These results suggest that for serious MSSA infections, the presence of a significant inoculum effect with cefazolin could be associated with clinical failure in patients treated with this cephalosporin, particularly when it is used at low doses.

Knowledge Graph

Similar Paper

Inoculum Effect with Cefazolin among Clinical Isolates of Methicillin-Susceptible Staphylococcus aureus : Frequency and Possible Cause of Cefazolin Treatment Failure
Antimicrobial Agents and Chemotherapy 2009.0
Determination of an Inoculum Effect with Various Cephalosporins among Clinical Isolates of Methicillin-Susceptible Staphylococcus aureus
Antimicrobial Agents and Chemotherapy 2010.0
Antimicrobial Activities of Ceftaroline and ME1036 Tested against Clinical Strains of Community-Acquired Methicillin-Resistant Staphylococcus aureus
Antimicrobial Agents and Chemotherapy 2008.0
In Vitro Activity of Ceftaroline against Streptococcus pneumoniae Isolates Exhibiting Resistance to Penicillin, Amoxicillin, and Cefotaxime
Antimicrobial Agents and Chemotherapy 2008.0
Effects of Ceftobiprole and Oxacillin on mecA Expression in Methicillin-Resistant Staphylococcus aureus Clinical Isolates
Antimicrobial Agents and Chemotherapy 2010.0
Activity of Ceftaroline against Recent Emerging Serotypes of Streptococcus pneumoniae in the United States
Antimicrobial Agents and Chemotherapy 2010.0
Prevalence of Serotype 19A Streptococcus pneumoniae among Isolates from U.S. Children in 2005-2006 and Activity of Faropenem
Antimicrobial Agents and Chemotherapy 2008.0
Clinical Outcomes by Methicillin-Resistant Staphylococcus aureus Staphylococcal Cassette Chromosome mec Type: Isolates Recovered from a Phase IV Clinical Trial of Linezolid and Vancomycin for Complicated Skin and Skin Structure Infections
Antimicrobial Agents and Chemotherapy 2010.0
In Vitro Activity of Ceftaroline against Community-Associated Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, and Daptomycin-Nonsusceptible Staphylococcus aureus Isolates
Antimicrobial Agents and Chemotherapy 2010.0
Restoration of Susceptibility of Intracellular Methicillin-ResistantStaphylococcus aureusto β-Lactams: Comparison of Strains, Cells, and Antibiotics
Antimicrobial Agents and Chemotherapy 2008.0